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Cells of the mouse macrophage-like cell line RAW,, release a dialysable inhibitor of phospholipase activity 
into their culture medium. This inhibitor can be detected in saline solution, Hanks solution and a variety 
of tissue culture media in the presence or absence of serum. The inhibitor is stable at 4”C, unaffected by 
trypsin, nucleases, or boiling, and partially extractable with chloroform/methanol. The release of both ara- 
chidonic acid and prostaglandins from mouse macrophages or human monocytes is inhibited by this materi- 
al. A variety of other cell types release the inhibitor, which is effective against stimulation of arachidonic 
acid release from cultured macrophages by zymosan, serum, immune complexes and the calcium ionophore 
A23187. 
Arachidonic acid Prostaglandin Phospholipase Macrophage 
1. INTRODUCTION 
The provision of free arachidonic acid is a rate 
limiting step in the production of prostaglandins 
and leukotrienes by macrophages presented with 
inflammatory stimuli [I]. Arachidonic acid is pres- 
ent at high concentrations in the cell membrane 
and lipid bodies of macrophages, mainly in the 
form of phospholipids [2]. These reserves can be 
mobilised by the action of phospholipase A2 
(PLAz), by either addition of exogenous enzyme or 
stimulation of one of the two macrophage PLA2 
activities [3,4], as well as by phospholipase C and 
diacylglycerol ipase action. Addition of PLAz in- 
hibitors such as mepacrine to stimulated 
macrophages lowers the amount of arachidonic 
acid released, with a consequent reduction in the 
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amount of prostaglandins produced. PLAz may 
thus play a pivotal role in the control of 
arachidonic acid metabolism and has been invoked 
as the site of action of various glucocorticoid hor- 
mone induced anti-inflammatory second messen- 
gers [5,6]. 
We have used primary macrophage cultures and 
the macrophage-like cell line RAW264 [7] to in- 
vestigate the control of macrophage PLAz activity 
in vitro. The release of 14C metabolites from 
macrophages pre-labelled with [i4C]arachidonic 
acid has been used as a measure of phospholipase 
activity. In addition, we have used a prostaglandin 
E2 (PGE2) radioimmunoassay as an indirect 
measure of changes in phospholipase activity. By 
means of these 2 assays, we have detected a small 
phospholipase inhibitory factor (SPLIF) in culture 
medium conditioned by the RAW264 cell line. Here 
we describe some of the properties of SPLIF, 
which is released by a variety of cell lines and is ac- 
tive in both murine macrophages and human 
monocytes. 
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2. MATERIALS AND METHODS 
BALB/c female mouse macrophages were 
prepared by culturing adherent cells from 
peritoneal avages in RPM1 1640, 10% FCS (Flow) 
supplemented with penicillin (100 units/ml) and 
streptomycin (100 pg/ml) for 24 h in 24 well plates 
(Linbro). RAW261 cells were cultured in the same 
medium. All incubations were carried out at 37°C 
in a 5% CO2 humidified atmosphere. Human 
monocytes were prepared by Ficoll/triosil gradient 
centrifugation from peripheral blood and cultured 
for 24 h in the same medium [S]. 
Phospholipase activity in cultured cells was 
assessed by incubating each well of a 24 well plate 
containing 2.5 x 10’ BALB/c peritoneal 
macrophages with 0.5 ml of 0.2 &i/ml [14C]- 
arachidonic acid (Amersham, 60 mCi/mM) in 
medium for 2 h. Cells were then washed 3 times 
with serum free RPMI, the test sample added, and 
counts released measured 45 min later by sam- 
pling, microfuging and counting aliquots in PCS 
scintillant (Amersham). All assays were carried out 
in duplicate or triplicate. 14C counts released were 
linear up to this time, and cultures stimulated with 
10% foetal calf serum (Flow) or zymosan 
(100 pug/ml, Sigma) gave 4-lo-times background 
release. 
PGE2 radioimmunoassay [9] was carried out on 
supernatant samples from cells plated into 48 well 
plates (Costar) (lo5 macrophages/well) after over- 
night incubation with test samples. All assays were 
carried out in triplicate. Stimulation of counts 
released correlates with increased PGE2 produc- 
tion by zymosan or FCS treated cultures. 
3. RESULTS 
3. I. SPLIF production in vitro 
We studied the appearance of SPLIF from con- 
fluent RAW264 cells incubated with fresh medium 
in the presence or absence of hydrocortisone 
hemisuccinate (fig.1). A maximal inhibition of 
[ 14C]arachidonic acid metabolite release of about 
50% was observed after 4 h of culture when super- 
natants were assayed on test macrophages. This ef- 
fect was also apparent in the presence of steroid. 
Thereafter, we used overnight culture supernatants 
from confluent RAWZ,+I cells. Comparing condi- 
tioned SPLIF containing medium with uncondi- 
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Fig.1. Release of 14C-labelled arachidonic acid 
metabolites from pre-labelled macrophages, treated for 
45 min with tissue culture supernatants (RPM1 1640, 
10% FCS), conditioned by RAW264 cells for various 
times in the presence (0) and absence (0) of 
hydrocortisone (1pg/ml). 
tioned controls, we found that the inhibition of 14C 
release was mirrored in a diminution of PGEz 
release, measured by immunoassay. Using 10% 
FCS stimulated macrophages, we found an inhibi- 
tion of overnight PGEz production from 
31.6 ng/ml (SE1.4) to 19.4 ng/ml (SE4) compar- 
ing conditioned with control RPMI. 
To determine whether we were measuring the 
appearance of an inhibitory activity or merely 
monitoring the exhaustion of a medium compo- 
nent essential for phospholipase activity, we 
prepared RAW264 conditioned solutions of serum 
free RPMI, Hanks solution and simple saline, and 
compared them with controls. Fig.2 demonstrates 
that SPLIF appears in the simplest saline solutions 
and we can therefore be confident that we are deal- 
ing with the appearance of an inhibitor. 
3.2. SPLIF inhibits the action of distinct 
inflammatory stimuli 
A variety of unrelated stimuli induce 
arachidonic acid release from macrophages [lo]. 
The metabolites produced are dependent upon the 
stimulus, perhaps because of distinct metabolic 
pools of arachidonic acid and pathways of 
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Fig.2. PGEz production by macrophages incubated 
overnight with RAW264 conditioned media (hatched) 
and controls. Conditioned saline (O.SScr/o NaCI) was 
diluted 1:3 (v/v) with RPM1 1640, and chloroform/ 
methanol extracts re-suspended in an equivalent volume 
of RPM1 1640 after lyophilisation. FCS was then added 
to a final concentration of 10%. 
mobilisation [ll]. The phagocytosis of zymosan 
has been shown to lead to the release of lysosomal 
PLAz with concomitant PGE2 production which is 
steroid inhibitable [12]. On the other hand, the 
calcium ionophore A23 187 which stimulates 
arachidonic acid mobilisation into lipoxygenase 
products is not inhibited by steroids [ 161. We 
tested a number of inflammatory stimuli on 
macrophages in the presence or absence of 
RAW264 derived SPLIF. Table 1 shows that SPLIF 
lowers the release of arachidonic acid derivatives 
by all stimuli investigated, including the calcium 
ionophore A23 187. 
3.3. SPLIF is released by, and acts upon, various 
cell types 
We tested the species specifically of RAW261 
SPLIF by measuring the release of [14C]ara- 
chidonic acid release from human monocytes. 
Fig.3 demonstrates that RAW264 SPLIF acts upon 
human monocytes to the same extent as mouse 
macrophages or RAW264 d.3. 
We next investigated medium conditioned by a 
Table 1 
Inhibition of [r4C]arachidonic acid metabolite release 
from macrophages by RAW264 conditioned RPM1 1640, 
using a variety of stimuli to elicit arachidonic acid 
release 
Stimulus % inhibition 
10% FCS 
100 pg/ml zymosan 
Monoclonal IgG2b ascites fluid 
10 pg/ml 
A23 187 calcium ionophore 
2.5 pg/ml 
55 
41 
33 
42 
variety of cell lines for SPLIF activity. Using the 
[‘4C]arachidonic acid release assay, we demon- 
strated SPLIF release from cultured macrophages. 
Endogenous PGE2 production by the generating 
cells did not allow us to test macrophage SPLIF on 
PGEz production by target macrophages, but 
using other cell lines which do not synthesize PGE2 
[ 13,151, we found non-adherent and non-macro- 
phage-like cells also release SPLIF into their 
100 
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Fig.3. Release of [14C]arachidonic acid metabolites from 
pre-labelled mouse peritoneal macrophages, RAW264 
cells [7], and human monocytes [8], stimulated for 
45 min with 10% FCS containing control and RAW264 
conditioned RPM1 1640 (hatched). 
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Fig.4. Macrophage PGE2 production in the presence of 
RPM1 1640, conditioned overnight (hatched) with either 
RAW264 cells, BP03 mouse hybridoma cells ([15] and 
Baxter, D., Coote, P., Wood, J., unpublished), orNB2 
lymphoma cells [ 131. 
culture medium (fig.4). All the cell-lines tested 
proved positive for SPLIF release. 
3.4. Characterisation of SPLIF activity 
SPLIF activity is lost from dialysates of condi- 
tioned medium. We prepared ultra-filtrates of con- 
trol and SPLIF containing RAW264 conditioned 
serum-free medium using Diaflo XM-10 (Amicon) 
filters. Fig.5 shows that the ultrafiltrate retains its 
SPLIF activity implying that the molecular mass is 
less than 10 kDa. These ultrafiltrates can be boiled 
for 5 min without loss of activity. Ultrafiltrates of 
conditioned medium, resterilised by millipore 
filtration have been stored for weeks at 4°C with 
no loss of activity. We attempted to identify the 
nature of SPLIF by enzymic degradation. Incuba- 
tion with trypsin (1 mg/ml), RNase A (0.1 mg/ml) 
or DNase I (0.1 mg/ml) (Sigma) for 90 min at 
37°C followed by boiling to inactivate the enzymes 
led to no loss of SPLIF activity, measured using 
the 14C release assay. We next tried chloroform/ 
methanol extraction of control and conditioned 
medium, and found (fig.2) a partial extraction of 
inhibitory activity, although less than that present 
in the original material. 
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Fig.5. RAW264 conditioned RPM1 1640 (hatched) after 
XM-10 ultrafiltration and boiling. Effect on 
macronhage 114Clarachidonic acid metabolite release 
-after 45 mm stimulation with 10% FCS. 
Ballou and Cheung have recently reported the 
pressure of an endogenous phospholipase in- 
hibitory activity in platelets [14]. This activity ap- 
pears to be associated with a mixture of un- 
saturated fatty acids [17]. We tested the hypothesis 
that SPLIF might also be such a mixture. When 
RAW264 conditioned Hanks solution is analysed 
by a thin layer chromatography on Whatman 
LKDF plates, using a solvent system of pen- 
tane : diethylether : acetic acid (80 : 20 : 1, v/v), a 
major band of inhibitory activity was found with 
an Rf of 0.61, running between palmitoleic acid 
and oleic acid standards (30% inhibitor of 14C 
release). It thus seems plausible that the activity 
described here is associated with the appearance of 
unsaturated fatty acids in conditioned medium. 
4. DISCUSSION 
We have demonstrated the presence of SPLIF in 
medium conditioned by a variety of cell lines. En- 
dogenous modulators of phospholipase activity are 
of considerable interest, not only for our 
understanding of the mechanism of arachidonic 
acid mobilisation into a variety of biologically ac- 
205 
Volume 189, number 2 FEBS LETTERS September 1985 
tive oxidation products, but also in the search for 
novel anti-inflammatory agents. The properties of 
SPLIF show similarities with those of an inhibitor 
recently identified in platelets [14] and subsequent- 
ly found to comprise a mixture of unsaturated fat- 
ty acids. The fact that SPLIF is released in simple 
salt solutions from many different cell types sug- 
gests that it may be a passively shed normal mem- 
brane constituent of a lipidic nature. TLC analysis 
confirms an association between the appearance of 
inhibitory activity and the presence of material 
comigrating with authentic unsaturated fatty acid 
markers. It thus appears likely that SPLIF and the 
inhibitory fraction isolated from platelets are 
closely related. Ballou and Cheung have shown 
that unsaturated fatty acids, including arachidonic 
acid, are potent non-competitive inhibitors of 
phospholipase activity [ 171. Our experiments how 
that such inhibition also results in lowered pros- 
taglandin synthesis, suggesting that arachidonic 
acid is not a component of SPLIF, and that un- 
saturated fatty acids may play an anti- 
inflammatory role by limiting the release of 
arachidonic acid. 
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